Tang Dominic H, Djajadiningrat Rosa, Diorio Gregory, Chipollini Juan, Ma Zhenjun, Schaible Braydon J, Catanzaro Mario, Ye Dingwei, Zhu Yao, Nicolai Nicola, Horenblas Simon, Johnstone Peter A S, Spiess Philippe E
Department of Urology, Moffitt Cancer Center, Tampa, FL.
Department of Urology, Antoni van Leeuwenhoek Hospital, Netherlands Cancer Institute, Amsterdam, Netherlands.
Urol Oncol. 2017 Oct;35(10):605.e17-605.e23. doi: 10.1016/j.urolonc.2017.06.001. Epub 2017 Jun 27.
Few studies have examined the role of radiation therapy in advanced penile squamous cell carcinoma. We sought to evaluate the association of adjuvant pelvic radiation with survival and recurrence for patients with penile cancer and positive pelvic lymph nodes (PLNs) after lymph node dissection.
Data were collected retrospectively across 4 international centers of patients with penile squamous cell carcinoma undergoing lymph node dissections from 1980 to 2013. Further, 92 patients with available adjuvant pelvic radiation status and positive PLNs were analyzed. Disease-specific survival (DSS) and recurrence were analyzed using the Kaplan-Meier method and multivariable Cox proportional hazards model.
43% (n = 40) of patients received adjuvant pelvic radiation after a positive PLN dissection. Median follow-up was 9.3 months (interquartile range: 5.2-19.8). Patients receiving adjuvant pelvic radiation had a median DSS of 14.4 months vs. 8 months in the nonradiation group, respectively (P = 0.023). Patients without adjuvant pelvic radiation were associated with worse overall survival (hazard ratio [HR] = 1.7; 95% CI: 1.01-2.92; P = 0.04) and DSS (HR = 1.9; 95% CI: 1.09-3.36; P = 0.02) on multivariable analysis. Median time to recurrence was 7.7 months vs. 5.3 months in the radiation and nonradiation arm, respectively (P = 0.042). Patients without adjuvant pelvic radiation was also independently associated with higher overall recurrence on multivariable analysis (HR = 1.8; 95% CI: 1.06-3.12; P = 0.03).
Adjuvant pelvic radiation is associated with improved survival and decreased recurrence in this population of patients with penile cancer with positive PLNs.
很少有研究探讨放射治疗在晚期阴茎鳞状细胞癌中的作用。我们试图评估辅助盆腔放疗与阴茎癌伴盆腔淋巴结清扫术后盆腔淋巴结阳性(PLN)患者的生存率和复发率之间的关系。
回顾性收集了1980年至2013年期间4个国际中心接受淋巴结清扫的阴茎鳞状细胞癌患者的数据。此外,对92例有辅助盆腔放疗状态且PLN阳性的患者进行了分析。采用Kaplan-Meier法和多变量Cox比例风险模型分析疾病特异性生存率(DSS)和复发情况。
43%(n = 40)的患者在PLN阳性清扫术后接受了辅助盆腔放疗。中位随访时间为9.3个月(四分位间距:5.2 - 19.8)。接受辅助盆腔放疗的患者中位DSS为14.4个月,而非放疗组为8个月(P = 0.023)。多变量分析显示,未接受辅助盆腔放疗的患者总生存率(风险比[HR] = 1.7;95%置信区间:1.01 - 2.92;P = 0.04)和DSS(HR = 1.9;95%置信区间:1.09 - 3.36;P = 0.02)较差。放疗组和非放疗组的中位复发时间分别为7.7个月和5.3个月(P = 0.042)。多变量分析还显示,未接受辅助盆腔放疗的患者总体复发率也较高(HR = 1.8;95%置信区间:1.06 - 3.12;P = 0.03)。
辅助盆腔放疗与该组阴茎癌伴PLN阳性患者的生存率提高和复发率降低相关。